Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin ...

Despite growing competition in the transthyretin amyloid cardiomyopathy (ATTR-CM) field, Alnylam is hoping its RNA ...

BlackRock Health Sciences Term Trust is a top pick for high-yield dividends in healthcare. Click here to find out why BMEZ ...

With TTR silencers, the reported mean reduction was approximately 80%, which is not reached until six months after starting chronic treatment. Now, we have observed that the very low levels of ...

Del Ray is known as a liberal enclave, with more than 80% of neighborhood votes cast for ... with Robert Crawford and Tyler Jeffrey of TTR Sotheby’s International Realty, who did not immediately ...

NEW YORK (AP) — To billionaire Elon Musk and his cost-cutting team at the Department of Government Efficiency, Karen Ortiz ...

The mansion was once a friary, housing as many as 80 Capuchin friars ... between is the truth,” said listing agent Brad Kappel of TTR Sotheby’s International. The property’s centerpiece ...

Bristol Myers Squibb obtained the exclusive global license for PRX019 for $80 million; as part of the ... non-native forms of the transthyretin (TTR) protein, is being developed by Novo Nordisk ...

Nevertheless, analysts expect Alnylam to claim about 80% of the market ... “The results from the NEURO-TTR study support a favourable benefit-risk profile for inotersen in patients with hATTR.